LLY - Lilly's olomorasib receives U.S. FDA 's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant adva
LLY - Lilly's olomorasib receives U.S. FDA 's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer - Click For Release
Story updates
11:45:39 AM UTC
SquawkNews
LLY lilly's olomorasib receives U.S. FDA's breakthrough therapy designation for the treatment of previously treated kras g12c-mutant advanced pancreatic cancer
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.